Home » Stocks » CYTH

Cyclo Therapeutics, Inc. (CYTH)

Stock Price: $7.25 USD -0.05 (-0.68%)
Updated May 12, 2021 4:00 PM EDT - Market closed
After-hours: $7.30 +0.05 (0.69%) May 12, 5:56 PM
Market Cap 46.21M
Revenue (ttm) 903,376
Net Income (ttm) -8.94M
Shares Out 6.36M
EPS (ttm) -5.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $7.25
Previous Close $7.30
Change ($) -0.05
Change (%) -0.68%
Day's Open 7.14
Day's Range 6.85 - 7.27
Day's Volume 80,699
52-Week Range 3.55 - 17.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

1 day ago - Business Wire

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

2 weeks ago - Business Wire

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

3 weeks ago - Business Wire

Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.

Other stocks mentioned: AGRX, CMPI, GORO, RYTM, WINT, WMPN
1 month ago - InvestorPlace

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

1 month ago - Business Wire

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

1 month ago - Business Wire

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

2 months ago - Business Wire

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

2 months ago - Business Wire

The Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has adopted a positive opinion on Cyclo Therapeutics Inc's (NASDAQ: CYTH) for Trappsol Cyclo for Niemann-Pick Type C (NPC1). The tre...

2 months ago - Benzinga

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

2 months ago - Business Wire

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicine...

2 months ago - Business Wire

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing cyclodextrin-based products for the...

2 months ago - Business Wire

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing cyclodextrin-based products for the...

2 months ago - Business Wire

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing cyclodextrin-based products for the...

3 months ago - Business Wire

Insider buying could be a bullish signal for a stock. Why? The insiders may sell for a number of reasons.

Other stocks mentioned: BRO, BSRR, CHMG, FAST, VIRI, SRGA
3 months ago - InvestorPlace

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing a cyclodextrin platform for the tre...

3 months ago - Business Wire

Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Dise...

Other stocks mentioned: VVOS, MRKR, THC
4 months ago - Benzinga

About CYTH

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Th... [Read more...]

Industry
Biotechnology
Founded
1990
Stock Exchange
NASDAQ
Ticker Symbol
CYTH
Full Company Profile

Financial Performance

In 2020, CYTH's revenue was $903,376, a decrease of -10.31% compared to the previous year's $1.01 million. Losses were -$8.94 million, 18.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CYTH stock is "Buy" and the 12-month stock price forecast is 25.00.

Price Target
$25.00
Analyst Consensus: Buy